Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT05018299 is recruiting with primary completion estimated Feb 2026. No public readout available as of Apr 2026. Multiple sources confirm ongoing status without results.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial is recruiting with primary completion in Feb 2026; no public results or readout available. All sources confirm ongoing status without efficacy data or positive/negative framing.
Found Apr 6, 2026, 2:12 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout was found. The latest public sources still describe NCT05018299 as ongoing, with no results reported yet. Sponsor materials mention ongoing enrollment and favorable safety only, which is insufficient to call the trial positive or negative.
Found Apr 3, 2026, 4:07 PMReviewed Apr 3, 2026, 4:47 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public Phase 2 efficacy readout was found for NCT05018299. The trial record still shows recruiting/ongoing, and the sponsor’s latest investor materials say enrollment finished in December 2025 with trial completion expected in May 2026 and unblinding/study report in Q3 2026. Without a trial-specific readout, direction cannot be classified.
Found Apr 1, 2026, 7:10 PMReviewed Apr 1, 2026, 7:16 PM